

# Nieves Martinez Chanza

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3516180/publications.pdf>

Version: 2024-02-01

12  
papers

219  
citations

1307594

7  
h-index

1372567

10  
g-index

12  
all docs

12  
docs citations

12  
times ranked

384  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials. <i>Cancers</i> , 2020, 12, 1945.	3.7	49
2	Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients. <i>Annals of Nuclear Medicine</i> , 2019, 33, 945-954.	2.2	32
3	Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. , 2020, 8, e001467.		22
4	<sup>68</sup> Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1191-1198.	5.0	22
5	The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges. <i>Cancer Treatment Reviews</i> , 2017, 53, 138-145.	7.7	20
6	Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. , 2020, 8, e000538.		19
7	Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news. <i>Cancer Treatment Reviews</i> , 2021, 99, 102239.	7.7	13
8	Systematic review of neoadjuvant therapy by immune checkpoint inhibitors before radical cystectomy: where do we stand?. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 663-672.	3.9	13
9	Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4517-4517.	1.6	9
10	Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions. <i>Cancers</i> , 2021, 13, 4341.	3.7	8
11	Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial). <i>BMC Cancer</i> , 2021, 21, 1292.	2.6	8
12	Safety and efficacy of immune checkpoint inhibitors (CPI) in metastatic renal cell cancer (RCC) and urothelial cancer (UC) patients (pts) with pre-existing autoimmune disorders (AD).. <i>Journal of Clinical Oncology</i> , 2019, 37, 653-653.	1.6	4